Fig. 7. MOMA provides improved copy number alteration prediction compared with the current state-of-the-art methods and predicts additional copy number alterations not achieved in previous studies.

We systematically predict common copy number alterations of colorectal cancer tissues and compare the prediction performance with that of PC-CHiP²⁸. The mean and range of AUROC are shown. A Prediction of common genetic deletions in patients with colon adenocarcinoma. B Prediction of common genetic amplification in patients with colon adenocarcinoma. C Prediction of common genetic deletions in patients with rectal adenocarcinoma. D Prediction of additional genetic deletions in colon adenocarcinoma. E Prediction of additional genetic amplifications in colon adenocarcinoma. F Prediction of additional genetic deletions in rectal adenocarcinoma. The error bars show the 95% confidence interval of the mean. In this analysis, 463 patients are in the COAD group, and 164 patients are in the READ group. Asterisks denote two-sided Wilcoxon signed-rank test P-value<0.05 when comparing the two groups.